Check for updates

OPEN ACCESS

EDITED BY Darius Widera, University of Reading, United Kingdom

REVIEWED BY

Stefano Lorenzetti, National Institute of Health (ISS), Italy Ali Kermanizadeh, University of Derby, United Kingdom

*CORRESPONDENCE András Dinnyés, ⊠ andras.dinnyes@biotalentum.hu

RECEIVED 07 June 2023 ACCEPTED 31 July 2023 PUBLISHED 16 August 2023

CITATION

Horánszky A, Shashikadze B, Elkhateib R, Lombardo SD, Lamberto F, Zana M, Menche J, Fröhlich T and Dinnyés A (2023), Proteomics and disease network associations evaluation of environmentally relevant Bisphenol A concentrations in a human 3D neural stem cell model. *Front. Cell Dev. Biol.* 11:1236243. doi: 10.3389/fcell.2023.1236243

COPYRIGHT

© 2023 Horánszky, Shashikadze, Elkhateib, Lombardo, Lamberto, Zana, Menche, Fröhlich and Dinnyés. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Proteomics and disease network associations evaluation of environmentally relevant Bisphenol A concentrations in a human 3D neural stem cell model

Alex Horánszky^{1,2}, Bachuki Shashikadze³, Radwa Elkhateib³, Salvo Danilo Lombardo^{4,5,6}, Federica Lamberto^{1,2}, Melinda Zana¹, Jörg Menche^{4,5,6,7}, Thomas Fröhlich³ and András Dinnyés^{1,2,8}*

¹BioTalentum Ltd., Gödöllő, Hungary, ²Department of Physiology and Animal Health, Institute of Physiology and Animal Nutrition, Hungarian University of Agriculture and Life Sciences, Gödöllő, Hungary, ³Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany, ⁴Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna, Austria, ⁵Department of Structural and Computational Biology, Center for Molecular Biology, University of Vienna, Vienna, Austria, ⁶CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria, ⁷Faculty of Mathematics, University of Vienna, Vienna, Austria, ⁸Department of Cell Biology and Molecular Medicine, University of Szeged, Szeged, Hungary

Bisphenol A (BPA) exposure is associated with a plethora of neurodevelopmental abnormalities and brain disorders. Previous studies have demonstrated BPAinduced perturbations to critical neural stem cell (NSC) characteristics, such as proliferation and differentiation, although the underlying molecular mechanisms remain under debate. The present study evaluated the effects of a repeated-dose exposure of environmentally relevant BPA concentrations during the in vitro 3D neural induction of human induced pluripotent stem cells (hiPSCs), emulating a chronic exposure scenario. Firstly, we demonstrated that our model is suitable for NSC differentiation during the early stages of embryonic brain development. Our morphological image analysis showed that BPA exposure at 0.01, 0.1 and $1 \mu M$ decreased the average spheroid size by day 21 (D21) of the neural induction, while no effect on cell viability was detected. No alteration to the rate of the neural induction was observed based on the expression of key neural lineage and neuroectodermal transcripts. Quantitative proteomics at D21 revealed several differentially abundant proteins across all BPA-treated groups with important functions in NSC proliferation and maintenance (e.g., FABP7, GPC4, GAP43, Wnt-8B, TPPP3). Additionally, a network analysis demonstrated alterations to the glycolytic pathway, potentially implicating BPA-induced changes to glycolytic signalling in NSC proliferation impairments, as well as the pathophysiology of brain disorders including intellectual disability, autism spectrum disorders, and amyotrophic lateral sclerosis (ALS). This study enhances the current understanding of BPA-related NSC aberrations based mostly on acute, often high dose exposures of rodent in vivo and in vitro models and human GWAS data in a novel human 3D cell-based model with real-life scenario relevant prolonged and low-level exposures, offering further mechanistic insights into the ramifications of BPA exposure on the developing human brain and consequently, later life neurological disorders.

KEYWORDS

bisphenol A, neural stem cells, human induced pluripotent stem cells, DOHaD, new approach methodology

1 Introduction

The Developmental Origins of Health and Disease (DOHaD) concept relates early-life environmental conditions, including chemical exposures, to metabolic and health status in adult life. These exposures are associated with the onset of non-communicable diseases throughout life, including brain disorders (Haugen et al., 2015; Fleming et al., 2018). BPA is an endocrine disrupting compound (EDC) commonly utilized as a chemical precursor in the industrial manufacturing of epoxy resins, polycarbonate plastics, food and drink packaging and many other items found in daily consumer life (Vandenberg et al., 2007; Porras et al., 2014). The use of BPA-containing products is widespread, which is concerning due to their capacity to depolymerize and leach into the environment, for example, into food and drink stored in cans and plastic containers (Brede et al., 2003; Munguía-López et al., 2005; Le et al., 2008). BPA has also contaminated the environment in the air, water, soil and dust, and therefore potential routes of human uptake include inhalation and dermal absorption, as well as dietary ingestion from contaminated food (Hartle et al., 2022).

It has been well documented that BPA exposure is associated with altered cognitive function and behaviour, as well as neurodevelopmental disorders (NDDs) and neurodegenerative diseases (NDs), such as Alzheimer's disease (AD), autism spectrum disorders (ASD), and schizophrenia (Brown, 2009; Rebolledo-Solleiro et al., 2021). BPA has been identified in human blood, fetal serum, and breast milk (Rebolledo-Solleiro et al., 2021) and its lipophilic properties enable its permeation across cell membranes, placenta, and fetal blood-brain-barrier (BBB) (Ikezuki et al., 2002; Balakrishnan et al., 2010) allowing it to affect embryonic and fetal stages of brain development (O'Shaughnessy et al., 2021).

Estimations suggest that human intake of BPA is approximately 1-5 ug/kg/day (Murata and Kang, 2018), and due to its abundance in the environment, many people are subjected to a chronic exposure (Welch and Mulligan, 2022). Importantly, previous studies demonstrate that BPA doses in the ng/kg/day range, significantly lower than estimated daily human intake, induce aberrations to brain development in animal models (Negri-Cesi, 2015; Welch and Mulligan, 2022). Exposure of the vulnerable fetal brain to environmental chemicals could cause disruption to early developmental processes; from neurulation, neuronal proliferation, differentiation, and migration, through to synaptogenesis, dendritic outgrowth and myelination (Schneider et al., 2003; Hornung et al., 2009; Guo et al., 2013; Ling et al., 2016; Huang et al., 2019; Chesnut et al., 2021; Kalloo et al., 2021). Primary neurulation is the earliest stage of fetal central nervous system (CNS) development, where the neuroectoderm is derived from the ectodermal germ layer and NSCs first appear in the developing brain (Nikolopoulou et al., 2017; Leibovitz et al., 2022).

Initially, brain growth is facilitated by NSC expansion via symmetric cell divisions, followed by asymmetric NSC divisions, producing an NSC and an intermediate neuronal progenitor (NPC) in the early stages of neurogenesis. Even though NPCs have a limited proliferative capacity compared to NSCs as they enter a "primed" state for neuronal differentiation, their division is maintained throughout neurogenesis, providing a renewing pool of progenitors for further neuronal/glial specification (Bergström and Forsberg-Nilsson, 2012; Suzuki et al., 2021). In attempts to clarify its effects on the fetal stages of brain development, several studies have explored the impact of BPA exposure on NSC populations. Both in vitro and in vivo investigations have described conflicting reports showing both increases and decreases to NSC proliferation depending on BPA concentration and duration of exposure. Notably, most in vitro studies used BPA treatments ranging from 24 h to 7 days, modelling the effects of acute exposure on already established NSCs, (Kim et al., 2007; Tiwari et al., 2015; Agarwal et al., 2016; Huang et al., 2019; Dong et al., 2021; Gill and Kumara, 2021), therefore the effects of BPA exposure on NSCs over longer time periods in vitro remain unexplored. The importance of acute toxicity testing of BPA for protecting the environment and public health cannot be understated. However, for an enhanced risk assessment of BPA's effects on neural development and its potential contributions to NDs and NDDs, improved in vitro models that can determine the longterm effects of BPA after repeated exposures are needed. Importantly, in chronic exposure conditions with sub-cytotoxic concentrations, cellular responses to BPA could be much more complex, especially when considering that BPA is known to exert its intracellular effects via the interference of several receptors including nuclear receptors and noncanonical steroid hormone receptors (Acconcia et al., 2015).

A tightly regulated balance between NSC proliferation and differentiation is vital for neurogenesis and proper brain functionality, and disruptions to this balance are frequently observed in NDDs (Chen et al., 2014; Ernst, 2016; Casas Gimeno et al., 2022). Several studies have already demonstrated that BPA disturbs these processes, at least in part, via disruptions to critical signalling pathways in NSC development, such as Wnt/B-Catenin, ERRα, TGF-β, JNK, CREB and p53 pathways (Liu et al., 2015; Liu et al., 2013; Tiwari et al., 2015; 2016; Dong et al., 2021; Welch and Mulligan, 2022). Despite the wide interest and extensive studies, the mechanisms underlying BPA-induced alterations to NSCs, and their possible associations to aberrant brain development, NDDs and NDs are still under debate and require further elucidation. Quantitative proteomic approaches utilize state-of-the-art technologies that can be applied to assess cellular proteome alterations after exposure with environmental chemicals, clarifying mechanisms of toxicity and improving chemical risk assessments (Gao et al., 2009). Proteomic-based methods are advantageous compared to transcriptomic methods, as they directly quantify protein levels rather than using transcript levels as a proxy. Therefore, proteomics can be used for a deeper understanding of the effects of BPA exposure directly on the protein expression levels of genes of interest.

HiPSCs are derived from reprogrammed somatic cells, and are characterized by their capabilities of self-renewal, proliferation, and differentiation into all three embryonic germ layers (Shi et al., 2017). The neuronal differentiation of hiPSCs provides a valuable platform for further study of the effects of environmental chemicals on the developmental processes of the human CNS, bridging the gap between data from animal models and human studies (Xie et al., 2020). 3D hiPSC-derived models are particularly promising; compared to 2D cell culture systems, 3D cultures more closely replicate complex human tissues of interest with regards to cell signalling, differentiation capacity and tissue organization, while they also display more realistic responses to environmental chemicals (Kobolak et al., 2020; Wang et al., 2023). The neural induction of hiPSCs to NSCs can be used as a representative *in vitro* model of the critical neurulation stage of embryonic brain development, where NSCs are first derived in the developing brain (Chambers et al., 2009; Galiakberova and Dashinimaev, 2020).

In the present study, for the first time, we performed a repeated-dose BPA exposure for 21 days from the initiation of the in vitro 3D neural induction of hiPSCs. Our human cell-based system facilitated further investigation of BPA-induced perturbations during the earliest stages of embryonic brain development over a longer-term exposure than previous in vitro studies, supporting previous data obtained from animal studies in a human relevant model. The expression of key neuroectodermal and neural lineage markers demonstrated that our system provides a robust model for NSC differentiation to investigate the effects of environmentally relevant BPA concentrations. This allowed us to support current literature and elucidate BPA-induced aberrations to NSC properties, such as inhibited proliferation. Additionally, we utilized a quantitative proteomics approach alongside a disease network analysis to investigate proteome-wide alterations in BPA-treated NSCs, uncovering novel BPA-induced molecular changes in NSCs that could be implicated in altered NSC properties during development and the pathophysiology of certain brain disorders.

2 Materials and methods

2.1 Chemicals and plasticware

Chemicals were purchased from Sigma-Aldrich (St Louis, MO, United States). Plasticware and reagents for cell culture were purchased from Thermo Fisher Scientific Inc (Waltham, MA, United States), unless stated otherwise.

2.2 hiPSC culture

The SBAD2 hiPSC line, derived from healthy adult dermal fibroblast (NHDF-Ad) cells (Lonza, Cat#: CC-2511, 51 years old Caucasian male) reprogrammed using non-integrative Sendai virus transduction, was used in this study. Cells were maintained *in vitro* in a humidified atmosphere that contained 5% CO₂ at 37°C. BD MatrigelTM matrix (BD Biosciences) was used for plate coating and cells were maintained with mTeSRTM1 medium (Stem Cell Technologies). EDTA (0.02% Versene, Cat#: BE17-711E, Lonza) was used for passaging cells every 5–7 days as described in the manufacturer's protocol. The Venor[®]GeM-Advance (Minerva Biolabs) *Mycoplasma* Detection Kit was used for routine *mycoplasma* screening, as described in the manufacturer's instructions. Representative characterization of the SBAD2 hiPSCs was performed previously, demonstrating normal stem cell characteristics including colony morphology, karyotype, and expression of pluripotency markers (Snijders et al., 2021; Fehér et al., 2022).

2.3 3D neural induction

The *in vitro* differentiation of hiPSCs to NSCs was carried out using the dual SMAD inhibition method (Chambers et al., 2009; Shi et al., 2012) to induce neuroectoderm formation. Upon reaching 90% confluence, the neural induction was initiated by replacing mTeSRTM1 medium with neural induction medium (NIM; Neurobasal medium: DMEM/F12, supplemented with 1x N2, 2x B27, 100 μ M β -mercaptoethanol, 2 mM glutamine, 1x non-essential amino acid (NEAA), 5 μ g/mL insulin) supplemented with 200 nM LDN-193189 HCL (Selleck Chemicals, cat# S7507), 10 μ M SB431542, and 5 ng/mL basic fibroblast growth factor (bFGF). The next day, hiPSCs were dissociated with Accutase[®] solution and seeded as single cells (10,000 cells/well) onto Prime Surface 96well V plates in 200 μ L NIM for spheroid formation. NIM was replaced every third day with a 75% media change, to minimize spheroid disturbance.

2.4 BPA-treated 3D neural induction

BPA stock solution was prepared by dissolving the compound in DMSO to a final concentration of 100 mM. BPA was further diluted to appropriate experimental concentrations using NIM. Repeated doses of 0.01, 0.1 and 1 μ M BPA were administered to spheroids at each medium change for 3 weeks following the initiation of the 3D neural induction (Figure 3C). Media change and BPA treatments were performed every third day to minimize spheroid disturbance. 75% of spent medium was exchanged with NIM containing concentrations of BPA that yielded the specified treatment concentrations. NIM supplemented with 0.1% DMSO was used as vehicle control throughout the experiment.

2.5 Immunocytochemical staining

3D NSC spheroids were fixed with 4% PFA in 0.1 mol/L phosphate buffer for 1 h at RT and subsequently washed 3 times with phosphate buffered saline (PBS). Spheroids were permeabilized with 0.2% TritonX-100 in PBS and blocked in 3% BSA in PBS at RT for 1 h. Spheroids were incubated with primary antibodies (Supplementary Table S1) overnight at 4°C. Spheroids were then washed 3 times in PBS before their incubation with isotype-specific secondary antibodies diluted in 3% BSA in PBS for 1 h at RT. Spheroids were washed 3 times in PBS and mounted on Superfrost[™] Ultra Plus Adhesion Slides (Thermo Fisher Scientific) using ProLong[™] Diamond Antifade Mountant with DAPI for nuclear labelling. Image acquisition was undertaken using a BX-41 epifluorescent microscope (objectives: ×20 0.50 NA; 40 × 0.75 NA; Olympus) fitted with a DP-74 digital camera and Cellsens software (V1.18; Olympus).

2.6 RT-qPCR

At each sampling timepoint, 16 spheroids were combined, and 3 independent experiments were performed (n = 3). RNA isolation was performed using either the RNeasy Plus Micro Kit (Qiagen), or

the RNeasy Plus Mini Kit (Qiagen). The Maxima First Strand cDNA Synthesis Kit for RT-qPCR with dsDNase (Thermo Fisher Scientific) was used for the reverse transcription using 1500 ng of the isolated RNA, as described in the manufacturer's protocol. Primer3 software was used to design gene-specific primers (Supplementary Table S2) and GAPDH was used as a reference gene. 5ng cDNA template was used for each qPCR reaction in addition to 50% SYBR Green JumpStart Taq ReadyMix and 400 nM of each primer, to a final volume of 15 µL. The QIAgility liquid handling robot and Rotor-Gene Q cycler (Qiagen) were used for experimental setup and qPCR reaction, respectively. The qPCR cycling protocol included 3 min at 94°C for denaturation and a subsequent 40 cycles of 5 s at 95°C, 15s at 60°C, and 30 s at 72°C. Primer specificity was confirmed via melting curve analysis. Fetal Brain RNA (Takara Bio, Cat# 636526) and human cortical RNA (Takara Bio, Cat# 636561) were used for normalization. The ddCT method (Livak and Schmittgen, 2001) was used to analyze data obtained from three technical replicates for each gene.

2.7 Cell viability and cytotoxicity assays

2.7.1 ATP viability assay

NSC spheroids were treated with increasing concentrations of BPA for 72 h (Figure 3A) to produce dose-response curves. In each experimental plate, 3 technical replicates were used for each concentration, and data were obtained from 3 independent assays (n = 3). Vehicle control was used as NIM supplemented with 0.1% DMSO. Paraquat was used as a positive neurotoxic control. CellTiter-Glo[®] 3D Cell Viability Assay (Promega) was used to perform the ATP viability assay, as described in the manufacturer's instructions. After BPA treatment, 100 µL CellTiter-Glo[®] 3D Reagent was added to the NSC spheroids for 1 h at RT. The luminescent signal was then recorded using a Thermo VarioScan Flash plate reader (Thermo Fisher Scientific).

2.7.2 LDH cytotoxicity assay

Spheroids were subjected to a repeated-dose exposure using nanomolar concentrations of BPA for 21 days during the neural induction process, as previously described (Figure 3C). For each BPA concentration and vehicle control, treated NIM was removed from triplicate wells at D14 and D21 of the BPA-treated neural induction to analyze LDH release. Cytotoxicity was calculated on day 14 and day 21 of BPA treatment using negative controls on the corresponding days. Three independent experiments were performed (n = 3). The CyQUANTTM LDH Cytotoxicity Assay (Thermo Fisher Scientific) was used to measure LDH levels from the collected medium to quantify cytotoxicity, as described in the manufacturer's protocol. The colorimetric signal was measured using a Thermo VarioScan Flash plate reader.

2.8 Spheroid size analysis

Vehicle-control, and BPA-treated NSC spheroids were imaged using the ×4 objective (0.1NA) of the Olympus IX71 microscope and DP21 camera (DP21). The captured images were analyzed via surface area measurements using the CellSens Dimension software (V1.11). Each value represents the average of 4 independent experiments (n = 4) where 8 spheroids at each concentration were measured.

2.9 Analysis of ROS and mitochondrial levels

NSC spheroids at D21 of the BPA treatment protocol were treated with 5 μ M CellROXTM Deep Red (Invitrogen) for 1 h at 37°C, or 100 nM MitoTracker Deep Red 633 (Invitrogen) for 30 m at 37°C, for the assessment of reactive oxygen species (ROS) and mitochondrial levels, respectively (ex/em; 630/650 nm). Spheroids were then fixed with 4% PFA in 0.1 mol/L phosphate buffer for 1 h at RT. The IncuCyte[®] Live Cell Analysis System (Sartorius, United States), was then used for image capture and quantification of the fluorescence signal (exposure time: 150 ms). Assessed spheroids were obtained from 3 independent experiments (n = 3).

2.10 Quantitative proteomics

2.10.1 Sample preparation

Cells were lysed in 8 M urea/0.5 M NH4HCO3 by ultrasonication (18 cycles of 10 s) using a Sonopuls HD3200 (Bandelin, Berlin, Germany). Proteins were quantified using Pierce 660 nm Protein Assay (Thermo Fisher Scientific, Rockford, IL, United States). 20 μ g of protein was reduced with 4 mM dithiothreitol (DTT) and 2 mM tris(2-carboxyethyl) phosphine (TCEP) at 56°C for 30 min and alkylated with 8 mM iodoacetamide (IAA) at room temperature in the dark. DTT was added to a final concentration of 10 mM to quench residual IAA during 15 min incubation in the dark. Proteins were digested with modified porcine trypsin (1:50 enzyme/protein ration, Promega) for 16 h at 37°C.

2.10.2 Nano-liquid chromatography (LC)-tandem mass spectrometry (MS/MS) analysis and statistics

1 µg of the digest was injected on an UltiMate 3000 nano-LC system coupled online to a Q-Exactive HF-X instrument (Thermo Fisher Scientific). Peptides were first transferred to a PepMap 100 C18 trap column (100 μ m × 2 cm, 5 μ M particles, Thermo Fisher Scientific) and separated on an analytical column (PepMap RSLC C18, 75 μ m × 50 cm, 2 μ m particles, Thermo Fisher Scientific) at 250 nL/min flow-rate with an 80-min gradient of 5%-20% of solvent B followed by a 9-min increase to 40%. Solvent A consisted of 0.1% formic acid in water and solvent B of 0.1% formic acid in acetonitrile. MS spectra were acquired using a top 15 datadependent acquisition method on a Q Exactive HF-X mass spectrometer. The dataset has been submitted to the ProteomeXchange Consortium via the PRIDE partner repository (Perez-Riverol et al., 2022) with the dataset identifier PXD042045. Raw file processing was performed using MaxQuant (Tyanova et al., 2016) using the human SwissProt reference proteome downloaded in October 2022. All statistical analyses and data visualization were performed in R using custom scripts. Proteins with at least two peptides detected in at least three samples of each condition were tested for differential abundance using the MS-EmpiRe (Ammar

et al., 2019) algorithm as described previously (Flenkenthaler et al., 2021). To handle missing values for peptides with measurements in all replicates of one condition and insufficient measurements in the other condition, data imputation with random numbers from the normal distribution (downshift 1.8, width 0.3) was performed. Proteins with a Benjamini–Hochberg corrected *p*-value ≤ 0.05 and fold-change ≥ 1.3 were regarded as significantly altered. For hierarchical clustering ComplexHeatmap R package (Gu et al., 2016) was used. The k-means algorithm was used for partitioning the heatmap into homogeneous regions. Overrepresentation analysis was performed using the WebGestaltR package (Liao et al., 2019) and the functional category 'GO Biological Process nonRedundant'. The false discovery rate was controlled using the Benjamini–Hochberg method.

2.11 Statistical analysis

Data is presented with the mean \pm standard error of the mean (SEM). All data, excluding proteomics analysis, was analyzed using Prism 7 (Graphpad Software, CA, United States) software. Statistical significance was determined using One-way ANOVA, or two-way ANOVA and Dunnett's post hoc test, where applicable. A *p*-value of <0.05 was considered significant.

2.12 Network analysis

2.12.1 Human protein-protein interaction (PPI) network construction and analysis

The human PPI network was built from publicly available resources (Menche et al., 2015; Alanis-Lobato et al., 2017; Luck et al., 2020), resulting in 18,816 proteins and 478,353 physical interactions.

Significantly changed proteins were mapped onto the human PPI network, and their connectivity was calculated by computing a z-score of the largest connected component for each group of proteins compared to 10,000 randomly selected protein sets of the same size. For each condition, we considered all differentially abundant proteins, as well as subdividing into up- and down-regulated proteins.

2.12.2 Enrichment analysis

Differentially abundant proteins and their respective connected core were biologically characterized by performing an enrichment analysis for the three main branches of the gene ontology (GO) (Ashburner et al., 2000): biological processes (BP), molecular functions (MF), and cellular components (CC), and for KEGG pathway (Kanehisa and Goto, 2000) using GSEAPY (Fang et al., 2023).

2.12.3 Disease predictions

Diseases-gene associations (GDA) were retrieved from DisGeNet (Piñero et al., 2015) which represents the largest publicly available collections of genes and variants associated with human diseases, including expert-curated associations from GWAS catalogues, animal models and scientific literature. Depending on the accuracy of the type of information, each gene-disease association is attributed with a GDA score that ranges from 0 to 1. We selected only associations with a GDA score >0.3, retrieving information for 11,099 diseases. The

relationship between each set of differentially abundant proteins (s1) and set of disease proteins (s2) was then computed in two different ways: 1) by calculating their Jaccard index (intersection (s1,s2)/union(s1,s2)), and by network proximity of the two sets (Guney et al., 2016). Network proximity computes the closest distance between two sets of proteins in a network and by comparing it against 10,000 random sets of similar topological features. In this way, we considered and corrected for interactome biases such as the heavy-tail degree distribution and the discretization of other common network distances like the shortest path.

The closest path between the differentially abundant proteins and the disease genes was computed by considering both the shortest path and the presence of hubs in the direct proximity of the two gene sets (source code available at: github.com/superlsd/ NetBPAbrain).

2.12.4 ALS candidate genes validation

Gene expression count data from human post-mortem spinal cords were downloaded from zenodo platform (Humphrey et al., 2023). The normalized Transcripts Per Kilobase Million (TPM) values of the two most relevant regions for disease progression (cervical and lumbar) were used for further statistical analyses. To compare the median expression of the connecting genes between ALS and BPA-downregulated genes in both ALS patients and controls, we performed a two-tailed *t*-test.

2.13 Ethical approval

The ethical licence was issued by the Scientific and Research Ethics Committee of the Hungarian Health Science Council for "Production of induced pluripotent stem cells (IPS) from human somatic samples" with the following ID No.: IV/3935- 1/2021/EKU in May 2021.

3 Results

3.1 The characterization of hiPSC-derived NSCs confirms the 3D neural induction as a robust *in vitro* model for NSC differentiation

We performed a characterization of the hiPSC-derived NSCs to assess the suitability of the 3D neural induction as an in vitro model for NSC differentiation. Upon initiation of the 21-day induction process via dual-SMAD inhibition, hiPSCs formed compact spheroids within 48 h. Furthermore, brightfield images demonstrated a consistent growth of spheroid size throughout the differentiation (Figure 1A). Next, we investigated the expression levels of key transcripts associated with NSCs throughout the neural induction, via RT-qPCR (Figure 1B). There was a significant increase in the relative expression of classical neuroectodermal markers Nestin and Sox1, and marker of NSC multipotency Sox2, by D7 of the differentiation. Over the course of the induction, progressive increases in the mRNA levels of genes critical to the neural lineage, such as Tubulin beta-3 chain (Tub3) and Vimentin, were accompanied by a marked decrease in the expression of pluripotency marker Oct-4 by D7. The expression



Characterization of hiPSC-derived NSCs. (A) Schematic overview and phase contrast images of the 3D *in vitro* neural induction of hiPSCs to NSCs. Scale bar, 200 μ m. (B) Real-time qPCR measurements of the 3D neural induction of hiPSCs. Graphs represent normalized relative expression values. GAPDH was used as a reference gene and data was normalized using Takara human cortical RNA. The results shown are from 3 independent experiments (*n* = 3). One-way ANOVA with Dunnett's post hoc test was used to determine significance (adjusted *p*-value * *p* < 0.05, ** *p* < 0.01). ± SEM are displayed. (C) Neuroectodermal and NSC markers were stained in 3D culture (x40 magnification). The used fluorophores were Alexa 488 (green) and Alexa 594 (red). Nuclei were counterstained with DAPI (blue). Scale bar, 50 μ m.

of Nestin, Sox1, Sox2 and Vimentin observed in Figure 1B was confirmed on a protein level using ICC detection of NSC spheroids at D21 of the neural induction (×40 magnification) (Figure 1C, Supplementary Figure S3).

For a deeper characterization of the hiPSC-derived NSCs, we investigated proteome alterations in an unbiased and comprehensive manner. To achieve this, we performed a label-free liquid chromatography-tandem mass spectrometry analysis (LC-MS/MS) of hiPSCs (D0, n = 5), and NSCs (D21, n = 5). A total of 4733 protein groups were identified with high confidence (false-discovery rate <0.01) (Supplementary Table S4A). The neural induction of hiPSCs led to the alteration of 60% of quantified proteins (Figures 2A, B, Supplementary Table S4B). Proteins being part of cytosolic transport, membrane docking, and nucleus organization were increased, while those involved in translational initiation, cytoplasmic translation, and rRNA metabolic processes were decreased (Figure 2C, Supplementary Tables S4B, C). Proteins with the highest increases in

abundance at D21 included typical NSC markers FABP7, DACH1 and DCX, and similarly other proteins typical of the neural lineage, such as MAP2, NCAM1 and MSI1 were elevated. Notably, there were increases to the abundance of neural lineage proteins Nestin, Vimentin, Sox2 and Tub3 at D21 compared to D0, in accordance with our RT-qPCR data (Figure 1B). In contrast, there was a decrease in the abundance of Yamanaka factor Oct-4, and pluripotency marker LIN28A in NSCs compared to hiPSCs.

3.2 Treatment with nanomolar concentrations of BPA had no effect on cellular viability during the neural induction

The hiPSC-derived NSCs were treated for 72 h with increasing concentrations of BPA (Figure 3A) and a cell viability assay was performed to determine sub-cytotoxic concentration levels in our



setting. A single-dose BPA treatment at 100 μ M significantly decreased NSC viability by 33% after 72 h. Conversely, concentrations of 0.01 μ M-50 μ M had no significant effect on NSC viability after 72 h BPA treatment, compared to the vehicle-treated control group (Figure 3B).

Having determined a sub-cytotoxic range of BPA concentrations that were aligned with environmentally realistic exposure levels (Ribeiro et al., 2017; 2019; Zahra et al., 2022), we performed the repeated-dose BPA exposure protocol using 0 μ M (vehicle control), 0.01, 0.1 and 1 μ M BPA during the neural induction of hiPSCs to NSCs (Figure 3C). Subsequently, we applied cytotoxicity assays to investigate whether a longer-term exposure to the selected concentrations would affect cell survival. At both D14 (Figure 3D) and D21 (Figure 3E) of the BPA-treated neural induction, no significant decreases in NSC viability (%) were observed in each treated group compared to the vehicle-treated control group.

3.3 Effects of a repeated-dose BPA exposure on NSC spheroid growth

To assess the effects of the repeated-dose BPA exposure on the growth rate during the 3D neural induction, we measured the surface area of differentiating spheroids from brightfield images obtained throughout the induction (Figure 4A). From D3 to D15, there were no significant differences in the size of spheroids in each treated group in comparison to the vehicle-treated group. Remarkably, by D21 of the induction, significant decreases in spheroid size were observed; compared to the vehicle control group, the mean spheroid sizes were reduced by 32%, 25%, and 27% in 0.01, 0.1 and 1 μ M BPA treated groups, respectively (Figure 4B).

3.4 Effects of BPA exposure on mitochondrial and ROS levels

To investigate alterations of mitochondrial levels in BPA-treated D21 NSC spheroids, we used MitoTracker Deep Red fluorescent probes, commonly utilized for viable cell staining of mitochondria. There was no significant difference in mean fluorescence intensity in each treated group compared to vehicle-treated control at D21 (Figures 5A, C); suggesting that BPA treatment induced no long-term alterations to mitochondrial levels after 21 days of treatment. Similarly, we assessed whether BPA treatment affected cellular ROS levels using CellROXTM Deep Red fluorescent probes. We observed no significant change to mean fluorescence levels in BPA-treated groups at D21 (Figures 5B, D), indicating that BPA treatment at our experimental concentrations had no effect on cellular ROS levels.



FIGURE 3

Cell viability and cytotoxicity measurement of NSC spheroids after BPA exposure. (A) Experimental schematic and (B) concentration-response representing the cell viability (%) of NSC spheroids (n = 3) upon 72 h BPA exposure. (C) Schematic outlining the repeated-dose BPA exposure during the 21-day neural induction, and LDH assay demonstrating viability (%) calculated from LDH release of NSC spheroids at (D) D14 (n = 3) and (E) D21 (n = 3) of the BPA treated neural induction. One-way ANOVA with Dunnett's post hoc test was used to determine significance (adjusted p-value *** p < 0.001) \pm SEM are displayed.



Microscopic aspect and growth curves of spheroids treated with increasing concentrations of BPA during the neural induction process. (A) The microscopic aspect of spheroids observed using the x4 objective (0.1 NA) of Olympus IX71 microscope and DP21 camera. Scale bar, 200 μ m. (B) Spheroid growth over 21 days from the beginning of the neural induction of hiPSCs with repeated dose exposure of 0.01, 0.1 and 1 μ M BPA. Vehicle (0 μ M) represents spheroids treated with 0.1% DMSO. Results displayed are from 4 independent experiments (n = 4). Two-way ANOVA with Dunnett's post hoc test was used to determine significance (adjusted p-value * p < 0.05, ** p < 0.01). \pm SEM are displayed.

3.5 Assessment of BPA-induced effects on NSC transcripts by RT-qPCR

To investigate potential changes to key NSC transcripts arising due to BPA exposure, and to determine whether there were alterations to the rate of hiPSC to NSC differentiation, we performed a weekly investigation of gene expression using RTqPCR during the neural induction (Figure 6). We measured the relative expression of key neuroectodermal markers Nestin and Sox1, as well as Sox2 and Tub3. No significant alterations in the



IncuCyte[®] Live Cell Analysis of mitochondra and KOS levels at D21 of the BPA-treated field induction. Images of D21 spheroids captured by the IncuCyte[®] Live Cell Analysis System for measurements of (**A**) mitochondrial and (**B**) ROS levels. Scale bar, 800 μ m. (**C**) Mean MitoTracker Deep Red fluorescence intensity of BPA treated spheroids at D21 quantified using the IncuCyte[®] Live Cell Analysis System. 0 μ M represents the vehicle-treated control groups. Three independent experiments were performed (*n* = 3). \pm SEM is displayed. One-way ANOVA with Dunnett's post hoc test was used to determine significance.

transcript expression levels of these genes were detected at D7, D14 or D21 in response to BPA exposure throughout the neural induction, suggesting that there was no change to the rate of the differentiation compared to controls.

3.6 Proteome remodelling effects of BPA treatment on the neural induction

To investigate the effect of BPA exposure on NSC proteome remodelling in an unbiased and comprehensive manner, we performed a label-free LC-MS/MS of NSCs treated with repeated doses of 0 μ M (vehicle control, n = 4), 0.01 μ M (n = 4), 0.1 μ M (n = 4) and 1 μ M (n = 4) BPA during the *in vitro* 3D neural induction (Figure 3C). Compared to the vehicle-treated control group, 11, 39 and 66 proteins were altered in abundance in 0.01, 0.1 and 1 μ M BPA-treated groups, respectively (Figures 7A–D, Supplementary Tables S4D–G). Interestingly, several proteins were consistently changed in abundance in all BPA-treated groups, regardless of concentration. These alterations included decreases to canonical

Wnt signalling protein Wnt-8b, and GAP43 (Neuromodulin), as well as GPC4, and TPPP3 (p20). Conversely, there was an increased abundance of FABP7 in all BPA-treated groups. No change was detected to the levels of key NSC proteins Nestin, Sox1, Sox2 and Tub3 in BPA-treated groups compared to the vehicle-treated control group at D21, in accordance with our RT-qPCR data (Figure 6). The observed alterations to the proteome profiles of BPA-treated NSCs demonstrate a dose-dependent increase in the quantity of differentially abundant proteins. Several of the proteins altered in abundance inclusively in all BPA-treated groups are involved in critical processes in NSC maintenance and fetal brain development.

3.7 Protein network mapping in BPA-treated NSCs

To gain a better understanding of the molecular interactions and roles of the differentially abundant proteins in disease, we extensively mapped them in a human protein-protein interaction (PPI) network consisting of 18,816 proteins and 478,353 physical



way ANOVA with Dunnett's post hoc test was used to determine significance. \pm SEM are displayed

interactions (Menche et al., 2015; Alanis-Lobato et al., 2017; Luck et al., 2020). Overall, we observed that the number of differentially abundant proteins and their connectivity in the PPI increased with increasing levels of BPA exposure (0.01 µM BPA p-value:3e-5, 0.1 µM BPA p-value: 1e-09, 1 µM BPA p-value: 2e-26. Supplementary Figure S5A), indicating a growing number of proteins that contribute to the same molecular processes in a dose-dependent manner. Notably, this trend was more pronounced for the downregulated proteins (Supplementary Figure S5B). Due to the observed dose-dependency of the results, we focused on proteins that exhibited downregulation at both 0.1 and 1 µM BPA concentrations. Among the 18 downregulated proteins that met this criterion, we observed 6 proteins (ENO1, ENO2, TPI1, PGAM1, ALDOA, and CKB) tightly interacting in the PPI (p-value: 1.2e-12), which we define as BPA-downregulated core (Figure 8A) and that resulted to be enriched for the glycolytic pathway and the HIF-1 signalling pathway (Figure 8B; Supplementary Table S7B).

At this point, intrigued by the potential pathological phenotype of this dysregulated core, we investigated its representation on a list of 11,099 diseases compiled from DisGeNET (Piñero et al., 2015) calculating for each pairwise combination of their genetic overlap by computing a Jaccard Index (see methods), finding a strong association with "Enzymopathy" (FDR: 3.3e-05) and "Acute Schizophrenia" (FDR:0.001) (Supplementary Table S7E).

To incorporate network topological features on the comparisons between the BPA-downregulated core and the diseases retrieved from DisGeNET, we used network proximity (Guney et al., 2016), identifying several neurological disorders on the predicted list, such as "Alzheimer's Disease" (FDR: 1e-06), "Amyotrophic Lateral Sclerosis" (FDR: 4e-07), and "Schizophreniform Disorders" (FDR: 4e-07) (Supplementary Table S7F).

To further understand the potential pathological implications of the BPA downregulated core proteins, we created a network that included these proteins and their shortest connections to a group of neurological disorders, including Schizophrenia, AD, Dementia, Depression, Autism behaviour, and ALS (Figure 8C). Most BPAperturbed proteins interact with hubs in the brain known to be involved in several neurological disorders, such as APP (Sun et al., 2008; Jakobsson et al., 2013) and ESR2 (Pinsonneault et al., 2013).

We observed that the observed changes in ALDOA and ENO1 expression could induce various neurological disorders by modulating their direct interactors. For example, ALDOA interacts with both HDAC, and GLO1, which have been previously associated with depression (Tsankova et al., 2006; McMurray et al., 2014; 2018). Similarly, ALDOA also interacts with SOD1, and FUS two of the few known causal genes in ALS (Miller et al., 2013; Deng et al., 2014).

To investigate this further, we analysed the transcriptomic expression of those genes that by interacting with ENO1 and ALDOA could lead to ALS in the largest ALS cohort to date (Humphrey, 2022). We found that their expression was



significantly lower in ALS patients compared to controls in the cervical and lumbar regions (Supplementary Tables S6A, B).

In summary, these results suggest that BPA may have a dosedependent effect on neurodevelopment by affecting not only the number of differentially expressed proteins, but also their interactions, potentially contributing to the impairment of the glycolytic metabolism, which is known to be altered in various neurological conditions.

4 Discussion

In recent years, several groups have investigated BPA-induced aberrations to the proliferative capacity of NSCs and NPCs, with conflicting results depending on BPA concentration and exposure duration. Studies using rat and human NSCs *in vitro* have demonstrated that BPA increased NSC proliferation and induced aberrant differentiation (Dong et al., 2021; Gill and Kumara, 2021). In contrast, studies have also shown that BPA

exposure causes decreased proliferation in mouse NSCs (Kim et al., 2007), impaired the proliferation of rat NSCs in vitro and in vivo (Tiwari et al., 2015; Agarwal et al., 2016), and human NSCs from umbilical cord blood (Huang et al., 2019). Additionally, studies have described BPA-induced impairments to NSC differentiation, for example, inhibited NSC differentiation (Agarwal et al., 2016; Huang et al., 2019; Dong et al., 2021) and conversely, premature neurogenesis (Kinch et al., 2015). These contrasting results may be attributed to the non-monotonic properties shared by BPA and other endocrine-disrupting compounds, rendering it difficult to reach a consensus regarding BPA effects on neural development across various experimental conditions (Vandenberg, 2014; Villar-Pazos et al., 2017). The effects of BPA may also diverge depending on the specific developmental timing of exposure. Notably, previous in vitro studies have focused on the effects of BPA on established NSC populations and their differentiation, overlooking the earlier differential processes of embryonic brain development, from which NSCs are derived.



Network analysis of BPA-downregulated core proteins. (A) Protein-Protein Interaction (PPI) Network of the 18 downregulated proteins in both 0.1 and 1 μ M BPA-treated groups. (B) BPA bubble plot of the top 15 enriched terms of the six BPA-downregulated core proteins. Bubbles are placed based on their -log10 *p*-value. Bubble size corresponds to the number of proteins that are found in each term, while their colour reflects the enrichment combined score (C) BPA downregulated core and disease-proteins network. Each node represents a protein, and its size is given by the global degree in the human PPI. The inner colour of each node represents whether that protein is one of the six BPA-downregulated core proteins (yellow), or a connecting protein (crange) or a disease-associated protein (colour-specific for each disease). If a protein is associated with more than 2 diseases, then the colour indigo will be used. The outlier color is used for BPA-downregulated core proteins that have already been observed to be associated with one or more diseases.

To date, there remains a lack of human relevant data on BPA exposure during brain development, as most currently available information was obtained from animal studies. In our study, we showed that our 3D *in vitro* system was an effective and stable model for hiPSC to NSC differentiation. Using RT-qPCR and ICC visualization, we found increases in the expression of typical

neuroectodermal and NSC markers, such as Nestin and Sox2, throughout the *in vitro* 3D neural induction on a protein and mRNA level. Furthermore, our proteomics study complemented this data, and consolidated the robustness of our model by demonstrating increases to a considerable number of key neural lineage and NSC markers by D21 (Červenka et al., 2021;

Galiakberova and Dashinimaev, 2020; Shin et al., 2007; Yun et al., 2012). Due to its human origin, this model, therefore, provides a new approach method (NAM), suitable for generating human relevant, highly translatable data for toxicity during the early stages of embryonic brain development. Despite the beneficial 3D microenvironment provided by spheroids, they are only comprised of a single cell type, in our case NSCs, and do not entirely reflect the intricate tissue structure of the developing brain (Augustyniak et al., 2019). Future studies investigating the effects of BPA on NSC development could therefore also utilize brain organoids, which closely replicate brain developmental processes. Organoids have a highly organized architecture and are comprised of several cell types, demonstrating considerable promise for toxicological study which can complement data regarding BPA effects obtained using NSC spheroids (Lancaster and Knoblich, 2014; Caipa Garcia et al., 2022).

Here, we examined the effects of nano to micromolar concentrations of BPA (0.01μ M -1μ M) that are aligned with environmentally relevant concentration levels (Ribeiro et al., 2017; 2019; Zahra et al., 2022). This concentration range allowed us to model, as closely as possible, the effects of a real-life, repeated environmental exposure to BPA in an *in vitro* setting. Performing a repeated-dose exposure during the 3D neural induction over 21 days encompassed the duration of the differentiation of hiPSCs to NSCs (Chambers et al., 2009; Galiakberova and Dashinimaev, 2020) and facilitated the investigation of the effects of BPA exposure on the *in vitro* neural induction of hiPSCs for the first time.

Our results demonstrated that cell viability levels were not affected after 14 or 21 days of the BPA-treated neural induction. This is in line with other *in vitro* studies that reported no change to the viability of neural stem and progenitor cells within the same concentration range of BPA, albeit after periods of acute exposure (Kim et al., 2007; Tiwari et al., 2015). The present study also showed a reduction in the spheroid size in all BPA-treated groups at D21, suggesting BPA exerted inhibitory effects on the proliferation of NSCs. These observations support current literature that demonstrated inhibited NSC/NPC proliferation upon BPA exposure (Kim et al., 2007; Tiwari et al., 2015; Huang et al., 2019; Rebolledo-Solleiro et al., 2021). Taken together, the reduced spheroid size in BPA-treated groups without alterations to cellular viability at D21 implied that molecular mechanisms were responsible for the observed changes.

Both in vitro and in vivo studies have demonstrated that BPA exposure can affect mitochondrial dynamics and cellular ROS levels in NSCs/NPCs, especially at higher concentrations (Kim et al., 2007; Agarwal et al., 2016; Kobayashi et al., 2020; Wang et al., 2021). In our study, we did not observe any significant alterations to cellular ROS and mitochondrial levels from a qualitative assessment at D21 of the BPA-treated neural induction in 0.01, 0.1, or 1 µM treated groups. However, due to light scatter and inadequate label penetrance into samples, end-point fluorescencebased imaging of fixed spheroids is mostly limited to the peripheral layers of cells, while it is also a possibility that short-term changes occurred at timepoints prior to D21 of the differentiation. Also, the quantification of ROS levels in vitro remains challenging, especially when considering that their abundance is continuously altered by various chemical reactions, diffusion, and compensatory mechanisms (Murphy et al., 2022).

Acute BPA exposure of established NSCs at concentrations of 1 μ M has been demonstrated to induce decreases to MAP2 and GFAP, markers of neuronal and glial specification respectively, as well as increases to NSC maintenance markers Nestin and Sox2 (Dong et al., 2021). Taking this into account along with previously discussed evidence that BPA perturbed NSC differentiation and neurogenesis, we investigated whether BPA affected the differentiation rate of hiPSCs to NSCs. In our study, no alterations were detected to the mRNA or protein levels of neuroectodermal markers Nestin and Sox1. Additionally, we detected no changes to the mRNA levels of Sox2, a marker of NSC multipotency in non-committed NSCs (Shimozaki, 2014), or Tub3, a typical marker of immature neurons that could indicate neuronal differentiation (Katsetos et al., 2003), suggesting there was no alteration to the rate of hiPSC to NSC differentiation.

To date, several studies have reported BPA-induced aberrations to vital molecular pathways that are important for proper NSC maintenance and neural differentiation. *In vivo* and *in vitro* rat models have shown that BPA disrupts the canonical Wnt signalling pathway, which has a critical influence on NSC/NPC proliferation and differentiation, as well as the pathophysiology of certain NDDs (Fang et al., 2015; Tiwari et al., 2015; Mulligan and Cheyette, 2016; Tiwari et al., 2016; Üstündağ and Emekli-Alturfan, 2020). Moreover, Dong et al., 2021 reported that a 1 μ M BPA treatment of human NSCs *in vitro* led to the modulation of ERRa, TGF- β and p53 signalling pathways, which maintain roles in the stemness maintenance of NSCs. However, the debate surrounding the molecular effects and consequences of BPA exposure on the developing fetal brain, and its associations to brain disorders, is ongoing.

To investigate the molecular perturbations to NSCs derived from the BPA-treated neural induction, we investigated proteomic alterations in BPA-treated groups. Proteomics analysis revealed several key proteins with functions related to the maintenance of NSC proliferation and differentiation that were significantly altered inclusively in 0.01, 0.1 and 1 µM-treated groups. We detected a decrease to Wnt-8b of the canonical Wnt signalling pathway in all treated groups. Interestingly, Wnt-8b is expressed in the neural tube, while it also plays a role in neuroectodermal patterning (Kim et al., 2002; Ciani and Salinas, 2005). A BPA-induced decrease to Wnt-8b could therefore affect the regional patterning specification of neural stem cells during development. Our findings of reduced Wnt-8b levels and spheroid size in all BPA-treated groups are supported by previous rat model studies that uncovered BPA-induced suppression of NSC proliferation due to aberrations to the canonical Wnt signalling pathway (Tiwari et al., 2015; Tiwari et al., 2016), and furthermore, for the first time, we confirmed that BPA can induce canonical Wnt alterations in a human NSC model.

In addition, we observed a decrease to Neuromodulin (GAP43) in all BPA-treated groups, a nervous system-specific protein required in mitotic neural progenitors (Brittis et al., 1995; Esdar et al., 1999). GAP43 is uniformly expressed in proliferating areas of the developing embryonic brain, while a lack of GAP43 expression results in suppressed neural progenitor proliferation (Kanazir et al., 1996; Mani et al., 2001; Mishra et al., 2008). Interestingly, the absence of GAP43 expression induces aberrations to the

differentiation and neural/glial commitment of multipotent precursor cells (Mani et al., 2001; Shen et al., 2004; 2008). Additionally, TPPP3 (p20) was decreased in all BPA-treated groups. TPPP3 is a cyclin-dependent kinase inhibitor and a member of the TPPP family, robust modulators of proliferation in most developmental processes (Oláh et al., 2017; Shukla et al., 2018). Knockdown/inhibition of TPPP3 has resulted in decreased proliferation and cell cycle arrest in various human and mouse tumour cell lines (Li et al., 2016; Oláh et al., 2022), suggesting it may play a role in the observed alterations to NSC proliferation.

Another protein decreased in all BPA-treated groups was Glypican-4 (GPC4), expressed by multipotent NSCs in the ventricular zone of the developing CNS. Upon NSC commitment, GPC4 expression desists (Hagihara et al., 2000). GPC4 depletion has also been demonstrated to affect the proliferation and maintenance of NSCs. Notably, GPC4 downregulation in NSCs tips the balance from maintaining the NSC pool in favour of intermediate progenitors (Fico et al., 2012), leading to the premature depletion of NSCs. Intriguingly, it has also been shown that the modulation of stem cell fate by GPC4 is primarily limited to the positive regulation of canonical Wnt signalling (Fico et al., 2012). Thus, the observed decreases to GPC4 in the present study provides a further mechanistic explanation to complement previous studies that implicated BPA-induced Wnt alterations in the suppression of NSC proliferation (Tiwari et al., 2015; Tiwari et al., 2016). Conversely, we observed an increase to FABP7 in all BPA-treated groups. FABP7 is expressed in neural stem/progenitors and during neuronal differentiation (Knobloch, 2017). FABP7 expression has been demonstrated to culminate during the transition of NSCs to radial glial progenitors and plays a role in their maintenance (Arai et al., 2005; Matsumata et al., 2016). Therefore, the increase of FABP7 in all treated groups could indicate that BPA-treated NSCs are at an advanced stage toward radial-glial progenitor transition.

Taken together, we uncovered BPA-induced changes to the levels of several proteins with important functional roles in NSC maintenance; supporting current literature and further elucidating potential molecular mechanisms implicated in the altered proliferation and differentiation of BPA-treated NSCs. The observed protein alterations could suggest that BPA-treated NSCs are at a more advanced differential stage in line with neural progenitors, which have a lower proliferative capacity. Therefore, it could be interesting for further study to distinguish whether BPA treatment precociously steers NSCs to a more 'primed' NPC state for neurogenesis, which could aid in the explanation of decreased proliferation and premature depletion of the NSC pool. A current caveat regarding the use of mass spectrometry-based proteomics is that peptides in low abundance may be under-sampled or altogether undetected due to dynamic range limitations, even when using cutting-edge mass spectrometers. Since proteins in low abundance, such as transcription factors, are often underrepresented in proteomic investigations, it remains a possibility that other important BPA-induced proteome alterations were undetected with this method. Future advancements to the sensitivity of mass spectrometry technology may enable issues with peptide abundances to be addressed, which would allow for more comprehensive investigations into the effects of BPA on the whole NSC proteome (Fonslow et al., 2011; Ding et al., 2013; Timp and Timp, 2020).

Our results demonstrated that BPA exposure at 0.1 and $1\,\mu M$ potentially contributed to the impairment of the glycolytic pathway.

Glycolysis is a critical metabolic process underlying NSC proliferation, and interestingly, several studies have demonstrated that glycolysis, rather than oxidative phosphorylation (OXPHOS), is the primary source of ATP synthesis in NSCs (Zheng et al., 2016; Iwata and Vanderhaeghen, 2021). The process of neurogenesis includes the proliferation of NSCs to NPCs, followed by neuronal differentiation. This is coupled with a progressive metabolic shift; as cells differentiate from NSC stage towards neurons, the predominant process for ATP synthesis transitions from glycolysis to OXPHOS (Zheng et al., 2016; Maffezzini et al., 2020; Iwata and Vanderhaeghen, 2021). Decreases to proteins of the glycolytic pathway could therefore also support the argument that BPA-treated NSCs are at a more advanced NPC stage as they begin to decrease glycolysis and advance their differential status. However, whether BPA-induced impairments to proliferation are a cause or a consequence of decreases to proteins of the glycolytic pathway is currently unclear.

Evidence from the present study and previous reports may explain the BPA-induced mechanisms leading to altered expression of proteins of the glycolytic pathway. BPA is known to bind to estrogen receptors (ERs), which are ubiquitously located, ligand-activated transcription factors. ERs modulate estrogen-dependent signalling pathways involved with the regulation of cell proliferation and differentiation in several cell types and tissues, including NSCs in the brain (Bustamante-Barrientos et al., 2021). Interestingly, ERs are known to exert their intracellular effects via PI3k/ATK signalling, an intracellular signalling pathway responsible for promoting proliferation, growth, and metabolism in response to extracellular stimuli (MacKay and Abizaid, 2018; Hoxhaj and Manning, 2020). The PI3K-Akt signalling pathway also maintains a critical role in the stimulation of glycolysis (Xie et al., 2019). A key downstream effector protein of this pathway includes HIF-1a of the HIF-1 signalling pathway. Although the oxygen-dependent regulation of HIF-1a is strongly associated with negative regulation by prolyl hydroxylases, HIF-1a is also modulated via PI3K/Akt signalling in nonhypoxic conditions (Masoud and Li, 2015). HIF-1 signalling plays a critical role in the regulation of metabolic enzymes and transporters that are responsible for promoting glycolysis (Kim et al., 2014; Del Rey et al., 2017). We observed decreases to proteins involved in the HIF-1 signalling pathway in 0.1 and 1 µM BPA-treated groups. Moreover, p53, another downstream effector of PI3K/Akt signalling, is involved in glycolytic suppression (Kim et al., 2014), and aberrations to p53 signalling have been previously reported in human NSCs after 1 µM BPA treatment (Dong et al., 2021). An exciting avenue for further research could therefore be the investigation of the metabolic status of BPA-treated NSCs and neurons. This could further uncover the role of BPA-induced glycolytic aberrations in the altered proliferation and differentiation reported after BPA treatment during neural developmental processes, which until now is relatively unexplored.

Many studies have pointed to the close connection between glycolytic brain metabolism, NDDs and NDs (Nascimento and Martins-de-Souza, 2015; Zhang et al., 2021; Li and Sheng, 2022). Metabolic gradients are fundamental factors in the regulation of NSC fate (Angelopoulos et al., 2022), and neural tube defects have been associated with the faulty regulation of glucose metabolism during pregnancy (Paddock et al., 2017; Keuls et al., 2020). Additionally, decreased glucose and oxygenation rates are linked to ageing and NDs (Camandola and Mattson, 2017), and to impairments of synaptogenesis during embryo development (Goyal et al., 2014).

Here, we show that BPA decreases the protein expression of members of the glycolytic pathway in NSCs, potentially leading to neurological defects that are not limited to the gestational period, and that could lead to NDDs and NDs. For instance, we showed that ENO1 and ALDOA interact with MED13, which has been associated with a broad range of NDDs including encephalopathy, intellectual disability, and autism (De Nardi et al., 2021; Trivisano et al., 2022). On the other side of the spectrum, we observed that glycolytic impairments could contribute to the onset of ALS through the interaction of ALDOA with SOD1, FUS, and ESR2. Interestingly, the decreased expression of ESR2, APP, and SPG7, direct interactors of ALDOA and ENO1 of the glycolytic pathway, has been confirmed in the cervical and lumbar regions of an independent cohort of ALS patients. Although there is currently a lack of evidence that directly connects BPA exposure to ALS, it remains a possibility that other physiological or metabolic disturbances induced by BPA, such as glycolytic defects, could play a role in ALS development. For instance, several pre-clinical studies suggest that altered CNS glucose metabolism and transport could lead to ALS progression (Tefera et al., 2021), and emerging reports from mouse model studies have demonstrated glycolytic impairments in ALS (Ferraiuolo et al., 2011; Tefera and Borges, 2019; Tefera et al., 2019). To summarize, we show that BPA exposure could lead to fundamental metabolic changes in the developing brain that could impair several critical developmental processes from neural tube formation to synaptogenesis, increasing the risk to develop several neurological disorders at any age in life.

In conclusion, we present a novel NAM for the investigation of toxic exposures on NSC differentiation during the earliest stages of CNS development. We demonstrated that a repeated-dose exposure over 21 days with sub-cytotoxic, environmentally relevant BPA concentrations decreased spheroid size during the neural induction of hiPSCs to NSCs, thus supporting previous literature showing that BPA inhibits the critical NSC property of proliferation. We identified BPAinduced alterations to several proteins with important functions in NSC proliferation and differentiation, and the glycolytic pathway, with implications for our understanding of the effects of BPA exposure on NSC maintenance and differentiation during embryonic brain development. In-line with the DOHaD concept, we provide further mechanistic insight into the links between BPA exposure during CNS development and several brain disorders, suggesting a role for BPAinduced changes to the glycolytic pathway in the pathophysiology of NDDs such as intellectual disability and ASD, as well as NDs including ALS.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics statement

Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.

Author contributions

AH prepared the experimental design, performed cell culturing, BPA spheroid treatments, size analysis, RT-qPCR, immunocytochemistry, viability assays, cellROX assays, Mitotracker assays, data analysis and interpretation, and drafted the manuscript. FL performed data interpretation, manuscript reviewing and editing. BS and RE performed LC-MS/MS and data analysis. SL performed network analysis and interpretation. MZ supervised the experimental design, data analysis, results interpretation, and manuscript writing. AD designed the research project, contributed to the interpretation of results and final revision of the manuscript. TF and JM participated in the interpretation of results, and manuscript revision. All authors contributed to the article and approved the submitted version.

Funding

This research has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 812660 (DohART-NET) and the Hungarian Grants Nos 2020-1.1.5-GYORSÍTÓSÁV-2021-00016 and TKP2021-EGA-28 from the National Research, Development and Innovation Fund.

Acknowledgments

We are grateful to Mária Bódi-Jakus (BioTalentum Ltd.) for training and ongoing support.

Conflict of interest

AH, FL, MZ, and AD were employed by BioTalentum Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2023.1236243/ full#supplementary-material

References

Acconcia, F., Pallottini, V., and Marino, M. (2015). Molecular mechanisms of action of BPA. *Dose-Response* 13 (4), 1559325815610582. doi:10.1177/1559325815610582

Agarwal, S., Yadav, A., Tiwari, S. K., Seth, B., Chauhan, L. K. S., Khare, P., et al. (2016). Dynamin-related protein 1 inhibition mitigates bisphenol A-mediated alterations in mitochondrial dynamics and neural stem cell proliferation and differentiation. *J. Biol. Chem.* 291 (31), 15923–15939. doi:10.1074/jbc.M115.709493

Alanis-Lobato, G., Andrade-Navarro, M. A., and Schaefer, M. H. (2017). HIPPIE v2.0: enhancing meaningfulness and reliability of protein–protein interaction networks. *Nucleic Acids Res.* 45 (D1), D408–D414. doi:10.1093/nar/gkw985

Ammar, C., Gruber, M., Csaba, G., and Zimmer, R. (2019). MS-EmpiRe utilizes peptide-level noise distributions for ultra-sensitive detection of differentially expressed proteins. *Mol. Cell. Proteomics* 18 (9), 1880–1892. doi:10.1074/mcp.RA119.001509

Angelopoulos, I., Gakis, G., Birmpas, K., Kyrousi, C., Habeos, E. E., Kaplani, K., et al. (2022). Metabolic regulation of the neural stem cell fate: unraveling new connections, establishing new concepts. *Front. Neurosci.* 16, 1009125. doi:10.3389/fnins.2022. 1009125

Arai, Y., Funatsu, N., Numayama-Tsuruta, K., Nomura, T., Nakamura, S., and Osumi, N. (2005). Role of Fabp7, a downstream gene of Pax6, in the maintenance of neuroepithelial cells during early embryonic development of the rat cortex. *J. Neurosci. Official J. Soc. Neurosci.* 25 (42), 9752–9761. doi:10.1523/JNEUROSCI. 2512-05.2005

Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., et al. (2000). Gene ontology: tool for the unification of biology. The gene ontology Consortium. *Nat. Genet.* 25 (1), 25–29. doi:10.1038/75556

Augustyniak, J., Bertero, A., Coccini, T., Baderna, D., Buzanska, L., and Caloni, F. (2019). Organoids are promising tools for species-specific *in vitro* toxicological studies. *J. Appl. Toxicol.* 39 (12), 1610–1622. doi:10.1002/jat.3815

Balakrishnan, B., Henare, K., Thorstensen, E. B., Ponnampalam, A. P., and Mitchell, M. D. (2010). Transfer of bisphenol A across the human placenta. *Am. J. Obstetrics Gynecol.* 202 (4), 393.e1–393.e7. doi:10.1016/j.ajog.2010.01.025

Bergström, T., and Forsberg-Nilsson, K. (2012). Neural stem cells: brain building blocks and beyond. Upsala J. Med. Sci. 117 (2), 132–142. doi:10.3109/03009734.2012. 665096

Brede, C., Fjeldal, P., Skjevrak, I., and Herikstad, H. (2003). Increased migration levels of bisphenol A from polycarbonate baby bottles after dishwashing, boiling and brushing. *Food Addit. Contam.* 20 (7), 684–689. doi:10.1080/0265203031000119061

Brittis, P. A., Meiri, K., Dent, E., and Silver, J. (1995). The earliest patterns of neuronal differentiation and migration in the mammalian central nervous system. *Exp. Neurol.* 134 (1), 1–12. doi:10.1006/exnr.1995.1031

Brown, J. S. (2009). Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia. *Schizophr. Bull.* 35 (1), 256–278. doi:10.1093/schbul/sbm147

Bustamante-Barrientos, F. A., Méndez-Ruette, M., Ortloff, A., Luz-Crawford, P., Rivera, F. J., Figueroa, C. D., et al. (2021). The impact of estrogen and estrogen-like molecules in neurogenesis and neurodegeneration: beneficial or harmful? *Front. Cell. Neurosci.* 15, 636176. doi:10.3389/fncel.2021.636176

Caipa Garcia, A. L., Arlt, V. M., and Phillips, D. H. (2022). Organoids for toxicology and genetic toxicology: applications with drugs and prospects for environmental carcinogenesis. *Mutagenesis* 37 (2), 143–154. doi:10.1093/mutage/geab023

Camandola, S., and Mattson, M. P. (2017). Brain metabolism in health, aging, and neurodegeneration. *EMBO J.* 36 (11), 1474–1492. doi:10.15252/embj.201695810

Casas Gimeno, G., and Paridaen, J. T. M. L. (2022). The symmetry of neural stem cell and progenitor divisions in the vertebrate brain. *Front. Cell Dev. Biol.* 10, 885269. doi:10. 3389/fcell.2022.885269

Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., and Studer, L. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat. Biotechnol.* 27 (3), 275–280. doi:10. 1038/nbt.1529

Chen, E. S., Gigek, C. O., Rosenfeld, J. A., Diallo, A. B., Maussion, G., Chen, G. G., et al. (2014). Molecular convergence of neurodevelopmental disorders. *Am. J. Hum. Genet.* 95 (5), 490–508. doi:10.1016/j.ajhg.2014.09.013

Chesnut, M., Paschoud, H., Repond, C., Smirnova, L., Hartung, T., Zurich, M.-G., et al. (2021). Human IPSC-derived model to study myelin disruption. *Int. J. Mol. Sci.* 22 (17), 9473. doi:10.3390/ijms22179473

Ciani, L., and Salinas, P. C. (2005). WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. *Nat. Rev. Neurosci.* 6 (5), 351–362. doi:10.1038/ nrn1665

De Nardi, L., Faletra, F., D'Adamo, A. P., Bianco, A. M. R., Athanasakis, E., Bruno, I., et al. (2021). Could the *MED13* mutations manifest as a Kabuki -like syndrome? *Am. J. Med. Genet. Part A* 185 (2), 584–590. doi:10.1002/ajmg.a.61994

Del Rey, M. J., Valín, Á., Usategui, A., García-Herrero, C. M., Sánchez-Aragó, M., Cuezva, J. M., et al. (2017). Hif-1 α knockdown reduces glycolytic metabolism and

induces cell death of human synovial fibroblasts under normoxic conditions. *Sci. Rep.* 7 (1), 3644. doi:10.1038/s41598-017-03921-4

Deng, H., Gao, K., and Jankovic, J. (2014). The role of FUS gene variants in neurodegenerative diseases. *Nat. Rev. Neurol.* 10 (6), 337-348. doi:10.1038/nrneurol. 2014.78

Ding, C., Chan, D. W., Liu, W., Liu, M., Li, D., Song, L., et al. (2013). Proteome-wide profiling of activated transcription factors with a concatenated tandem array of transcription factor response elements. *Proc. Natl. Acad. Sci.* 110 (17), 6771–6776. doi:10.1073/pnas.1217657110

Dong, P., Ye, G., Tu, X., Luo, Y., Cui, W., Ma, Y., et al. (2021). Roles of ERR α and TGF- β signaling in stemness enhancement induced by 1 μ M bisphenol A exposure via human neural stem cells. *Exp. Ther. Med.* 23 (2), 164. doi:10.3892/etm.2021.11087

Ernst, C. (2016). Proliferation and differentiation deficits are a major convergence point for neurodevelopmental disorders. *Trends Neurosci.* 39 (5), 290–299. doi:10.1016/j.tins.2016.03.001

Esdar, C., Oehrlein, S. A., Reinhardt, S., Maelicke, A., and Herget, T. (1999). The protein kinase C (PKC) substrate GAP-43 is already expressed in neural precursor cells, colocalizes with PKCeta and binds calmodulin. *Eur. J. Neurosci.* 11 (2), 503–516. doi:10. 1046/j.1460-9568.1999.00455.x

Fang, Z., Liu, X., and Peltz, G. (2023). GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. *Bioinforma. Oxf. Engl.* 39 (1), btac757. doi:10.1093/bioinformatics/btac757

Fang, Z., Liu, X., Yang, X., Song, X., and Chen, X. (2015). Effects of Wnt/ β -catenin signaling on bisphenol A exposure in male mouse reproductive cells. *Mol. Med. Rep.* 12 (4), 5561–5567. doi:10.3892/mmr.2015.4028

Fehér, A., Schnúr, A., Muenthaisong, S., Bellák, T., Ayaydin, F., Várady, G., et al. (2022). Establishment and characterization of a novel human induced pluripotent stem cell line stably expressing the iRFP720 reporter. *Sci. Rep.* 12 (1), 9874. doi:10.1038/s41598-022-12956-1

Ferraiuolo, L., Higginbottom, A., Heath, P. R., Barber, S., Greenald, D., Kirby, J., et al. (2011). Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. *Brain* 134 (9), 2627–2641. doi:10. 1093/brain/awr193

Fico, A., De Chevigny, A., Egea, J., Bösl, M. R., Cremer, H., Maina, F., et al. (2012). Modulating Glypican4 suppresses tumorigenicity of embryonic stem cells while preserving self-renewal and pluripotency. *Stem Cells* 30 (9), 1863–1874. doi:10.1002/ stem.1165

Fleming, T. P., Watkins, A. J., Velazquez, M. A., Mathers, J. C., Prentice, A. M., Stephenson, J., et al. (2018). Origins of lifetime health around the time of conception: causes and consequences. *Lancet (London, Engl.* 391 (10132), 1842–1852. doi:10.1016/S0140-6736(18)30312-X

Flenkenthaler, F., Ländström, E., Shashikadze, B., Backman, M., Blutke, A., Philippou-Massier, J., et al. (2021). Differential effects of insulin-deficient diabetes mellitus on visceral vs. Subcutaneous adipose tissue—multi-omics insights from the Munich MIDY pig model. *Front. Med.* 8, 751277. doi:10.3389/fmed.2021.751277

Fonslow, B. R., Carvalho, P. C., Academia, K., Freeby, S., Xu, T., Nakorchevsky, A., et al. (2011). Improvements in proteomic metrics of low abundance proteins through proteome equalization using ProteoMiner prior to MudPIT. J. Proteome Res. 10 (8), 3690–3700. doi:10.1021/pr200304u

Galiakberova, A. A., and Dashinimaev, E. B. (2020). Neural stem cells and methods for their generation from induced pluripotent stem cells *in vitro. Front. Cell Dev. Biol.* 8, 815. doi:10.3389/fcell.2020.00815

Gao, Y., Holland, R. D., and Yu, L.-R. (2009). Quantitative proteomics for drug toxicity. *Briefings Funct. Genomics Proteomics* 8 (2), 158–166. doi:10.1093/bfgp/elp006

Gill, S., and Kumara, V. M. R. (2021). Comparative neurodevelopment effects of bisphenol A and bisphenol F on rat fetal neural stem cell models. *Cells* 10 (4), 793. doi:10.3390/cells10040793

Goyal, M. S., Hawrylycz, M., Miller, J. A., Snyder, A. Z., and Raichle, M. E. (2014). Aerobic glycolysis in the human brain is associated with development and neotenous gene expression. *Cell Metab.* 19 (1), 49–57. doi:10.1016/j.cmet.2013.11.020

Gu, Z., Eils, R., and Schlesner, M. (2016). Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* 32 (18), 2847–2849. doi:10.1093/bioinformatics/btw313

Guney, E., Menche, J., Vidal, M., and Barábasi, A.-L. (2016). Network-based in silico drug efficacy screening. Nat. Commun. 7 (1), 10331. doi:10.1038/ncomms10331

Guo, B.-Q., Yan, C.-H., Cai, S.-Z., Yuan, X.-B., and Shen, X.-M. (2013). Low level prenatal exposure to methylmercury disrupts neuronal migration in the developing rat cerebral cortex. *Toxicology* 304, 57–68. doi:10.1016/j.tox.2012.11.019

Hagihara, K., Watanabe, K., Chun, J., and Yamaguchi, Y. (2000). Glypican-4 is an FGF2-binding heparan sulfate proteoglycan expressed in neural precursor cells. *Dev. Dyn. Official Publ. Am. Assoc. Anatomists* 219 (3), 353–367. doi:10.1002/1097-0177(2000)999999995::AID-DVDY1059>3.0.CO;2-#

Hartle, J. C., Zawadzki, R. S., Rigdon, J., Lam, J., and Gardner, C. D. (2022). Development and evaluation of a novel dietary bisphenol A (BPA) exposure risk tool. *BMC Nutr.* 8 (1), 143. doi:10.1186/s40795-022-00634-4

Haugen, A. C., Schug, T. T., Collman, G., and Heindel, J. J. (2015). Evolution of DOHaD: the impact of environmental health sciences. *J. Dev. Orig. Health Dis.* 6 (2), 55–64. doi:10.1017/S2040174414000580

Hornung, R. W., Lanphear, B. P., and Dietrich, K. N. (2009). Age of greatest susceptibility to childhood lead exposure: a new statistical approach. *Environ. Health Perspect.* 117 (8), 1309–1312. doi:10.1289/ehp.0800426

Hoxhaj, G., and Manning, B. D. (2020). The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. *Nat. Rev. Cancer* 20 (2), 74–88. doi:10. 1038/s41568-019-0216-7

Huang, M., Li, Y., Wu, K., Hao, S., Cai, Q., Zhou, Z., et al. (2019). Effects of environmental chemicals on the proliferation and differentiation of neural stem cells. *Environ. Toxicol.* 34 (12), 1285–1291. doi:10.1002/tox.22829

Humphrey, J. (2022). Gene expression count data from human post-mortem spinal cord: doi:10.5281/ZENODO.6385747

Humphrey, J., Venkatesh, S., Hasan, R., Herb, J. T., de Paiva Lopes, K., Küçükali, F., et al. (2023). Integrative transcriptomic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial activation and suggests new risk genes. *Nat. Neurosci.* 26 (1), 150–162. doi:10.1038/s41593-022-01205-3

Ikezuki, Y., Tsutsumi, O., Takai, Y., Kamei, Y., and Taketani, Y. (2002). Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. *Hum. Reprod.* 17 (11), 2839–2841. doi:10.1093/humrep/17.11.2839

Iwata, R., and Vanderhaeghen, P. (2021). Regulatory roles of mitochondria and metabolism in neurogenesis. *Curr. Opin. Neurobiol.* 69, 231–240. doi:10.1016/j.conb. 2021.05.003

Jakobsson, J., Zetterberg, H., Blennow, K., Johan Ekman, C., Johansson, A. G. M., and Landén, M. (2013). Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. *Neuropsychopharmacology* 38 (4), 664–672. doi:10.1038/npp.2012.231

Kalloo, G., Wellenius, G. A., McCandless, L., Calafat, A. M., Sjodin, A., Sullivan, A. J., et al. (2021). Chemical mixture exposures during pregnancy and cognitive abilities in school-aged children. *Environ. Res.* 197, 111027. doi:10.1016/j.envres. 2021.111027

Kanazir, S., Ruzdijic, S., Vukosavic, S., Ivkovic, S., Milosevic, A., Zecevic, N., et al. (1996). GAP-43 mRNA expression in early development of human nervous system. *Mol. Brain Res.* 38 (1), 145–155. doi:10.1016/0169-328X(96)00008-3

Kanehisa, M., and Goto, S. (2000). Kegg: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 (1), 27–30. doi:10.1093/nar/28.1.27

Katsetos, C. D., Legido, A., Perentes, E., and Mörk, S. J. (2003). Class III β -tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. *J. Child Neurology* 18 (12), 851–866. discussion 867. doi:10. 1177/088307380301801205

Keuls, R. A., Kojima, K., Lozzi, B., Steele, J. W., Chen, Q., Gross, S. S., et al. (2020). MiR-302 regulates glycolysis to control cell-cycle during neural tube closure. *Int. J. Mol. Sci.* 21 (20), 7534. doi:10.3390/ijms21207534

Kim, D.-Y., Rhee, I., and Paik, J. (2014). Metabolic circuits in neural stem cells. Cell. Mol. Life Sci. CMLS 71 (21), 4221–4241. doi:10.1007/s00018-014-1686-0

Kim, K., Son, T. G., Kim, S. J., Kim, H. S., Kim, T. S., Han, S. Y., et al. (2007). Suppressive effects of bisphenol A on the proliferation of neural progenitor cells. *J. Toxicol. Environ. Health, Part A* 70 (15–16), 1288–1295. doi:10.1080/ 15287390701434216

Kim, S.-H., Shin, J., Park, H.-C., Yeo, S.-Y., Hong, S.-K., Han, S., et al. (2002). Specification of an anterior neuroectoderm patterning by Frizzled8a-mediated Wnt8b signalling during late gastrulation in zebrafish. *Development* 129 (19), 4443–4455. doi:10.1242/dev.129.19.4443

Kinch, C. D., Ibhazehiebo, K., Jeong, J.-H., Habibi, H. R., and Kurrasch, D. M. (2015). Low-dose exposure to bisphenol A and replacement bisphenol S induces precocious hypothalamic neurogenesis in embryonic zebrafish. *Proc. Natl. Acad. Sci. U. S. A.* 112 (5), 1475–1480. doi:10.1073/pnas.1417731112

Knobloch, M. (2017). The role of lipid metabolism for neural stem cell regulation. Brain Plast. 3 (1), 61-71. doi:10.3233/BPL-160035

Kobayashi, K., Liu, Y., Ichikawa, H., Takemura, S., and Minamiyama, Y. (2020). Effects of bisphenol A on oxidative stress in the rat brain. *Antioxidants* 9 (3), 240. doi:10. 3390/antiox9030240

Kobolak, J., Teglasi, A., Bellak, T., Janstova, Z., Molnar, K., Zana, M., et al. (2020). Human induced pluripotent stem cell-derived 3D-neurospheres are suitable for neurotoxicity screening. *Cells* 9 (5), 1122. doi:10.3390/cells9051122

Lancaster, M. A., and Knoblich, J. A. (2014). Generation of cerebral organoids from human pluripotent stem cells. *Nat. Protoc.* 9 (10), 2329–2340. doi:10.1038/nprot.2014.158

Le, H. H., Carlson, E. M., Chua, J. P., and Belcher, S. M. (2008). Bisphenol A is released from polycarbonate drinking bottles and mimics the neurotoxic actions of estrogen in developing cerebellar neurons. *Toxicol. Lett.* 176 (2), 149–156. doi:10.1016/j.toxlet.2007.11.001

Leibovitz, Z., Lerman-Sagie, T., and Haddad, L. (2022). Fetal brain development: regulating processes and related malformations. *Life* 12 (6), 809. doi:10.3390/life12060809

Li, S., and Sheng, Z.-H. (2022). Energy matters: presynaptic metabolism and the maintenance of synaptic transmission. *Nat. Rev. Neurosci.* 23 (1), 4–22. doi:10.1038/ s41583-021-00535-8

Li, Y., Xu, Y., Ye, K., Wu, N., Li, J., Liu, N., et al. (2016). Knockdown of Tubulin polymerization promoting protein family member 3 suppresses proliferation and induces apoptosis in non-small-cell lung cancer. *J. Cancer* 7 (10), 1189–1196. doi:10.7150/jca.14790

Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z., and Zhang, B. (2019). WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Res.* 47 (W1), W199–W205. doi:10.1093/nar/gkz401

Ling, W., Endo, T., Kubo, K., Nakajima, K., Kakeyama, M., and Tohyama, C. (2016). *In utero* bisphenol A exposure induces abnormal neuronal migration in the cerebral cortex of mice. *Front. Endocrinol.* 7, 7. doi:10.3389/fendo.2016.00007

Liu, R., Xing, L., Kong, D., Jiang, J., Shang, L., and Hao, W. (2013). Bisphenol A inhibits proliferation and induces apoptosis in micromass cultures of rat embryonic midbrain cells through the JNK, CREB and p53 signaling pathways. *Food Chem. Toxicol.* 52, 76–82. doi:10.1016/j.fct.2012.10.033

Liu, Z.-H., Yang, Y., Ge, M.-M., Xu, L., Tang, Y., Hu, F., et al. (2015). Bisphenol-A exposure alters memory consolidation and hippocampal CA1 spine formation through Wnt signaling *in vivo* and *in vitro. Toxicol. Res.* 4 (3), 686–694. doi:10.1039/C4TX00093E

Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods (San Diego, Calif.)* 25 (4), 402–408. doi:10.1006/meth.2001.1262

Luck, K., Kim, D.-K., Lambourne, L., Spirohn, K., Begg, B. E., Bian, W., et al. (2020). A reference map of the human binary protein interactome. *Nature* 580 (7803), 402–408. doi:10.1038/s41586-020-2188-x

MacKay, H., and Abizaid, A. (2018). A plurality of molecular targets: the receptor ecosystem for bisphenol-A (BPA). *Hormones Behav.* 101, 59–67. doi:10.1016/j.yhbeh. 2017.11.001

Maffezzini, C., Calvo-Garrido, J., Wredenberg, A., and Freyer, C. (2020). Metabolic regulation of neurodifferentiation in the adult brain. *Cell. Mol. Life Sci.* 77 (13), 2483–2496. doi:10.1007/s00018-019-03430-9

Mani, S., Shen, Y., Schaefer, J., and Meiri, K. F. (2001). Failure to express GAP-43 during neurogenesis affects cell cycle regulation and differentiation of neural precursors and stimulates apoptosis of neurons. *Mol. Cell. Neurosci.* 17 (1), 54–66. doi:10.1006/mcne.2000.0931

Masoud, G. N., and Li, W. (2015). HIF-1a pathway: role, regulation and intervention for cancer therapy. Acta Pharm. Sin. B 5 (5), 378–389. doi:10.1016/j.apsb.2015.05.007

Matsumata, M., Inada, H., and Osumi, N. (2016). Fatty acid binding proteins and the nervous system: their impact on mental conditions. *Neurosci. Res.* 102, 47–55. doi:10. 1016/j.neures.2014.08.012

McMurray, K. M. J., Distler, M. G., Sidhu, P. S., Cook, J. M., Arnold, L. A., Palmer, A. A., et al. (2014). Glo1 inhibitors for neuropsychiatric and anti-epileptic drug development. *Biochem. Soc. Trans.* 42 (2), 461–467. doi:10.1042/BST20140027

McMurray, K. M. J., Ramaker, M. J., Barkley-Levenson, A. M., Sidhu, P. S., Elkin, P. K., Reddy, M. K., et al. (2018). Identification of a novel, fast-acting GABAergic antidepressant. *Mol. Psychiatry* 23 (2), 384–391. doi:10.1038/mp.2017.14

Menche, J., Sharma, A., Kitsak, M., Ghiassian, S. D., Vidal, M., Loscalzo, J., et al. (2015). Disease networks. Uncovering disease-disease relationships through the incomplete interactome. *Science* 347 (6224), 1257601. doi:10.1126/science.1257601

Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., et al. (2013). An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. *Lancet Neurology* 12 (5), 435–442. doi:10.1016/S1474-4422(13)70061-9

Mishra, R., Kumar Gupta, S., Meiri, K. F., Fong, M., Thostrup, P., Juncker, D., et al. (2008). GAP-43 is key to mitotic spindle control and centrosome-based polarization in neurons. *Cell Cycle* 7 (3), 348–357. doi:10.4161/cc.7.3.5235

Mulligan, K. A., and Cheyette, B. N. R. (2016). Neurodevelopmental perspectives on Wnt signaling in psychiatry. *Complex Psychiatry* 2 (4), 219–246. doi:10.1159/ 000453266

Munguía-López, E. M., Gerardo-Lugo, S., Peralta, E., Bolumen, S., and Soto-Valdez, H. (2005). Migration of bisphenol A (BPA) from can coatings into a fatty-food simulant and tuna fish. *Food Addit. Contam.* 22 (9), 892–898. doi:10.1080/02652030500163674

Murata, M., and Kang, J.-H. (2018). Bisphenol A (BPA) and cell signaling pathways. *Biotechnol. Adv.* 36 (1), 311–327. doi:10.1016/j.biotechadv.2017.12.002

Murphy, M. P., Bayir, H., Belousov, V., Chang, C. J., Davies, K. J. A., Davies, M. J., et al. (2022). Guidelines for measuring reactive oxygen species and oxidative damage in cells and *in vivo*. *Nat. Metab.* 4 (6), 651–662. doi:10.1038/s42255-022-00591-z

Nascimento, J. M., and Martins-de-Souza, D. (2015). The proteome of schizophrenia. NPJ Schizophr. 1, 14003. doi:10.1038/npjschz.2014.3

Negri-Cesi, P. (2015). Bisphenol A interaction with brain development and functions. Dose-Response 13 (2), 1559325815590394. doi:10.1177/1559325815590394 Nikolopoulou, E., Galea, G. L., Rolo, A., Greene, N. D. E., and Copp, A. J. (2017). Neural tube closure: cellular, molecular and biomechanical mechanisms. *Development* 144 (4), 552–566. doi:10.1242/dev.145904

Oláh, J., Lehotzky, A., Szénási, T., Berki, T., and Ovádi, J. (2022). Modulatory role of TPPP3 in microtubule organization and its impact on alpha-synuclein pathology. *Cells* 11 (19), 3025. doi:10.3390/cells11193025

Oláh, J., Szénási, T., Szunyogh, S., Szabó, A., Lehotzky, A., and Ovádi, J. (2017). Further evidence for microtubule-independent dimerization of TPPP/p25. *Sci. Rep.* 7 (1), 40594. doi:10.1038/srep40594

O'Shaughnessy, K. L., Fischer, F., and Zenclussen, A. C. (2021). Perinatal exposure to endocrine disrupting chemicals and neurodevelopment: how articles of daily use influence the development of our children. *Best Pract. Res. Clin. Endocrinol. Metabolism* 35 (5), 101568. doi:10.1016/j.beem.2021.101568

Paddock, M., Akram, R., Jarvis, D. A., Armitage, P., Song, S., Madhuvrata, P., et al. (2017). The assessment of fetal brain growth in diabetic pregnancy using *in utero* magnetic resonance imaging. *Clin. Radiol.* 72 (5), 427.e1–427.e8. doi:10.1016/j.crad.2016.12.004

Perez-Riverol, Y., Bai, J., Bandla, C., García-Seisdedos, D., Hewapathirana, S., Kamatchinathan, S., et al. (2022). The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. *Nucleic Acids Res.* 50 (D1), D543–D552. doi:10.1093/nar/gkab1038

Piñero, J., Queralt-Rosinach, N., Bravo, À., Deu-Pons, J., Bauer-Mehren, A., Baron, M., et al. (2015). DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. *Database J. Biol. Databases Curation* 2015, bav028. doi:10.1093/database/bav028

Pinsonneault, J. K., Sullivan, D., Sadee, W., Soares, C. N., Hampson, E., and Steiner, M. (2013). Association study of the estrogen receptor gene ESR1 with postpartum depression--a pilot study. *Archives Women's Ment. Health* 16 (6), 499–509. doi:10.1007/s00737-013-0373-8

Porras, S. P., Heinälä, M., and Santonen, T. (2014). Bisphenol A exposure via thermal paper receipts. *Toxicol. Lett.* 230 (3), 413-420. doi:10.1016/j.toxlet.2014.08.020

Rebolledo-Solleiro, D., Castillo Flores, L. Y., and Solleiro-Villavicencio, H. (2021). Impact of BPA on behavior, neurodevelopment and neurodegeneration. *Front. Biosci.* (*Landmark Ed.* 26 (2), 363–400. doi:10.2741/4898

Ribeiro, E., Delgadinho, M., and Brito, M. (2019). Environmentally relevant concentrations of bisphenol A interact with doxorubicin transcriptional effects in human cell lines. *Toxics* 7 (3), 43. doi:10.3390/toxics7030043

Ribeiro, E., Ladeira, C., and Viegas, S. (2017). Occupational exposure to bisphenol A (BPA): a reality that still needs to Be unveiled. *Toxics* 5 (3), 22. doi:10.3390/toxics5030022

Schneider, J. S., Huang, F. N., and Vemuri, M. C. (2003). Effects of low-level lead exposure on cell survival and neurite length in primary mesencephalic cultures. *Neurotoxicology Teratol.* 25 (5), 555–559. doi:10.1016/S0892-0362(03)00018-7

Shen, Y., Mani, S., and Meiri, K. F. (2004). Failure to express GAP-43 leads to disruption of a multipotent precursor and inhibits astrocyte differentiation. *Mol. Cell. Neurosci.* 26 (3), 390–405. doi:10.1016/j.mcn.2004.03.004

Shen, Y., Mishra, R., Mani, S., and Meiri, K. F. (2008). Both cell-autonomous and cell non-autonomous functions of GAP-43 are required for normal patterning of the cerebellum *in vivo. Cerebellum* 7 (3), 451–466. doi:10.1007/s12311-008-0049-5

Shi, Y., Inoue, H., Wu, J. C., and Yamanaka, S. (2017). Induced pluripotent stem cell technology: a decade of progress. *Nat. Rev. Drug Discov.* 16 (2), 115–130. doi:10.1038/nrd. 2016.245

Shi, Y., Kirwan, P., and Livesey, F. J. (2012). Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. *Nat. Protoc.* 7 (10), 1836–1846. doi:10.1038/nprot.2012.116

Shimozaki, K. (2014). Sox2 transcription network acts as a molecular switch to regulate properties of neural stem cells. *World J. Stem Cells* 6 (4), 485–490. doi:10.4252/ wjsc.v6.i4.485

Shin, S., Sun, Y., Liu, Y., Khaner, H., Svant, S., Cai, J., et al. (2007). Whole genome analysis of human neural stem cells derived from embryonic stem cells and stem and progenitor cells isolated from fetal tissue. *Stem Cells* 25 (5), 1298–1306. doi:10.1634/ stemcells.2006-0660

Shukla, V., Popli, P., Kaushal, J. B., Gupta, K., and Dwivedi, A. (2018). Uterine TPPP3 plays important role in embryo implantation via modulation of β -catenin. *Biol. Reproduction* 99 (5), 982–999. doi:10.1093/biolre/ioy136

Snijders, K. E., Fehér, A., Táncos, Z., Bock, I., Téglási, A., van den Berk, L., et al. (2021). Fluorescent tagging of endogenous Heme oxygenase-1 in human induced pluripotent stem cells for high content imaging of oxidative stress in various differentiated lineages. *Archives Toxicol.* 95 (10), 3285–3302. doi:10.1007/s00204-021-03127-8

Sun, X., Steffens, D. C., Au, R., Folstein, M., Summergrad, P., Yee, J., et al. (2008). Amyloid-associated depression: a prodromal depression of alzheimer disease? *Archives General Psychiatry* 65 (5), 542–550. doi:10.1001/archpsyc.65.5.542

Suzuki, H., Imajo, Y., Funaba, M., Nishida, N., Sakamoto, T., and Sakai, T. (2021). Current concepts of neural stem/progenitor cell therapy for chronic spinal cord injury. *Front. Cell. Neurosci.* 15, 794692. doi:10.3389/fncel.2021.794692 Tefera, T. W., Bartlett, K., Tran, S. S., Hodson, M. P., and Borges, K. (2019). Impaired pentose phosphate pathway in the spinal cord of the hSOD1G93A mouse model of amyotrophic lateral sclerosis. *Mol. Neurobiol.* 56 (8), 5844–5855. doi:10.1007/s12035-019-1485-6

Tefera, T. W., and Borges, K. (2019). Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. J. Cereb. Blood Flow Metabolism Official J. Int. Soc. Cereb. Blood Flow Metabolism 39 (9), 1710–1724. doi:10.1177/0271678X18764775

Tefera, T. W., Steyn, F. J., Ngo, S. T., and Borges, K. (2021). CNS glucose metabolism in amyotrophic lateral sclerosis: a therapeutic target? *Cell and Biosci.* 11 (1), 14. doi:10. 1186/s13578-020-00511-2

Timp, W., and Timp, G. (2020). Beyond mass spectrometry, the next step in proteomics. Sci. Adv. 6 (2), eaax8978. doi:10.1126/sciadv.aax8978

Tiwari, S. K., Agarwal, S., Seth, B., Yadav, A., Ray, R. S., Mishra, V. N., et al. (2015). Inhibitory effects of bisphenol-A on neural stem cells proliferation and differentiation in the rat brain are dependent on wnt/ β -catenin pathway. *Mol. Neurobiol.* 52 (3), 1735–1757. doi:10.1007/s12035-014-8940-1

Tiwari, S. K., Agarwal, S., Tripathi, A., and Chaturvedi, R. K. (2016). Bisphenol-A mediated inhibition of hippocampal neurogenesis attenuated by curcumin via canonical Wnt pathway. *Mol. Neurobiol.* 53 (5), 3010–3029. doi:10.1007/s12035-015-9197-z

Trivisano, M., De Dominicis, A., Micalizzi, A., Ferretti, A., Dentici, M. L., Terracciano, A., et al. (2022). MED13 mutation: a novel cause of developmental and epileptic encephalopathy with infantile spasms. *Seizure* 101, 211–217. doi:10.1016/j.seizure.2022. 09.002

Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., and Nestler, E. J. (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. *Nat. Neurosci.* 9 (4), 519–525. doi:10.1038/nn1659

Tyanova, S., Temu, T., and Cox, J. (2016). The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat. Protoc.* 11 (12), 2301–2319. doi:10. 1038/nprot.2016.136

Üstündağ, Ü. V., and Emekli-Alturfan, E. (2020). Wnt pathway: a mechanism worth considering in endocrine disrupting chemical action. *Toxicol. Industrial Health* 36 (1), 41–53. doi:10.1177/0748233719898989

Vandenberg, L. N., Hauser, R., Marcus, M., Olea, N., and Welshons, W. V. (2007). Human exposure to bisphenol A (BPA). *Reprod. Toxicol.* 24 (2), 139–177. doi:10.1016/j. reprotox.2007.07.010

Vandenberg, L. N. (2014). Non-monotonic dose responses in studies of endocrine disrupting chemicals: bisphenol a as a case study. *Dose-Response* 12 (2), 1. response.1. dose-response. doi:10.2203/dose-response.13-020.vandenberg

Villar-Pazos, S., Martinez-Pinna, J., Castellano-Muñoz, M., Alonso-Magdalena, P., Marroqui, L., Quesada, I., et al. (2017). Molecular mechanisms involved in the non-monotonic effect of bisphenol-a on Ca2+ entry in mouse pancreatic β -cells. *Sci. Rep.* 7 (1), 11770. doi:10.1038/s41598-017-11995-3

Wang, C., He, J., Xu, T., Han, H., Zhu, Z., Meng, L., et al. (2021). Bisphenol A(BPA), BPS and BPB-induced oxidative stress and apoptosis mediated by mitochondria in human neuroblastoma cell lines. *Ecotoxicol. Environ. Saf.* 207, 111299. doi:10.1016/j. ecoenv.2020.111299

Wang, H., Xu, T., and Yin, D. (2023). Emerging trends in the methodology of environmental toxicology: 3D cell culture and its applications. *Sci. Total Environ.* 857, 159501. doi:10.1016/j.scitotenv.2022.159501

Welch, C., and Mulligan, K. (2022). Does bisphenol A confer risk of neurodevelopmental disorders? What we have learned from developmental neurotoxicity studies in animal models. *Int. J. Mol. Sci.* 23 (5), 2894. doi:10.3390/ijms23052894

Xie, J., Wettschurack, K., and Yuan, C. (2020). Review: *in vitro* cell platform for understanding developmental toxicity. *Front. Genet.* 11, 623117. doi:10.3389/fgene.2020.623117

Xie, Y., Shi, X., Sheng, K., Han, G., Li, W., Zhao, Q., et al. (2019). PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). *Mol. Med. Rep.* 19 (2), 783–791. doi:10.3892/mmr.2018.9713

Yun, S.-W., Leong, C., Zhai, D., Tan, Y. L., Lim, L., Bi, X., et al. (2012). Neural stem cell specific fluorescent chemical probe binding to FABP7. *Proc. Natl. Acad. Sci. U. S. A.* 109 (26), 10214–10217. doi:10.1073/pnas.1200817109

Zahra, A., Kerslake, R., Kyrou, I., Randeva, H. S., Sisu, C., and Karteris, E. (2022). Impact of environmentally relevant concentrations of bisphenol A (BPA) on the gene expression profile in an *in vitro* model of the normal human ovary. *Int. J. Mol. Sci.* 23 (10), 5334. doi:10.3390/ijms23105334

Zhang, X., Alshakhshir, N., and Zhao, L. (2021). Glycolytic metabolism, brain resilience, and Alzheimer's disease. *Front. Neurosci.* 15, 662242. doi:10.3389/fnins. 2021.662242

Zheng, X., Boyer, L., Jin, M., Mertens, J., Kim, Y., Ma, L., et al. (2016). Metabolic reprogramming during neuronal differentiation from aerobic glycolysis to neuronal oxidative phosphorylation. *ELife* 5, e13374. doi:10.7554/eLife.13374